Dr. Richard A. Newcomb, MD

Dr. Newcomb practices at Massachusetts General Hospital in Boston, Massachusetts, part of Mass General Brigham.

Dr. Newcomb's NPI, 1902326143, was assigned on June 20, 2017. Dr. Newcomb graduated from University of Chicago, Pritzker School of Medicine in 2017. Dr. Newcomb holds Massachusetts license 281629.

Dr. Newcomb's primary practice is Massachusetts General Hospital, at 55 Fruit Street, Boston, MA 02114 in Suffolk County. The practice phone is (617) 726-2000.

Dr. Newcomb's primary practice is Massachusetts General Hospital in Boston, Massachusetts, part of Mass General Brigham. Dr. Newcomb is also affiliated with Brigham and Women's Hospital. The medical group on file is Massachusetts General Physicians Organization (MGPO). Dmand AI also links Dr. Newcomb to 1 more hospital, 3 group practices and clinics, 2 medical groups and 1 community health center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Newcomb practices, 7 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Newcomb's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Newcomb is licensed in Massachusetts.

CMS data shows 417 Medicare services from Dr. Newcomb across 4 procedure codes in 2024, for 92 Medicare patients. Medicare paid $39,467 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 92 Medicare patients who saw Dr. Newcomb in 2024. The largest group is 65 to 74, with 60 patients. 75% of them have high blood pressure, and 72% have high cholesterol. 20% are also on Medicaid. Their average risk score is 3.75, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Newcomb's median patient age at 67, with 37% women.

In 2024, Dr. Newcomb wrote 168 Medicare Part D claims for 13 patients. 71% of them were for generic drugs. CMS names the drug for 96 of them, across 7 drugs with 11 or more claims each, at $313,282 in total drug cost. In 2020, CMS named 122 claims across 7 drugs.

Dr. Newcomb accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Newcomb as offering telehealth.

Dmand AI links 49 papers to Dr. Newcomb, published from 2017 to 2025. 2024 was the busiest year, with 11. The most frequent topics are Hematopoietic Stem Cell Transplantation, Hematologic Neoplasms and Depression. Dr. Newcomb has published most often in Transplant Cell Ther. Dr. Newcomb's most frequent co-authors are Hermioni L. Amonoo, MD, Ryan David Nipp, MD and Tejaswini More Dhawale, MD.

CMS Open Payments shows 22 general payments to Dr. Newcomb from 9 drug and device companies from 2020 to 2025. Consulting fees make up the largest share, 92% of the total. Sanofi and Genzyme US Companies paid the most, $13,319.

Dr. Newcomb graduated from University of Chicago, Pritzker School of Medicine in 2017.